Meloxicam Meloxicam is a selective COX inhibitor, used to relieve pain and fever effects. In vitro
Meloxicam significantly reduces HCA-7 and Moser-S colony size. Meloxicam significantly inhibits HCA-7 colony and tumor growth but has no effect on the growth of the COX-2 negative HCT-116 cells. Meloxicam inhibits PGE(2) production, proliferation and invasiveness especially in MG-63 cells, which express relatively high levels of COX-2. Meloxicam causes apoptosis and upregulates Bax mRNA and protein in MG-63 cell culture.
In vivo
Meloxicam suppresses LM-8 tumor growth and lung metastasis in vivo mouse model. Meloxicam causes a significant reduction in lameness at post injection hour (PIH) 8 and 24 and tends to reduce effusion in horse. Meloxicam significantly suppresses synovial fluid (SF) prostaglandin E2 and substance P release at PIH 8 and bradykinin at PIH 24 compared to placebo treatment in horse. Meloxicam reduces general MMP activity at PIH 8 and 24 in horse. Meloxicam- or flunixin-treated horses has improved postoperative pain scores and clinical variables, compared with SS-treated horses. Meloxicam results in high numbers of neutrophils in ischemia-injured tissue of horse. Meloxicam administration significantly suppresses PGE2 concentrations in blood and synovial fluid at days 7 and 21, but has no effect on concentrations of TXB2 in blood or PGE2 in gastric mucosa in dogs. Cell Data
